These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 19704343)

  • 21. Crescentic glomerulonephritis associated with vascular endothelial growth factor (VEGF) inhibitor and bisphosphonate administration.
    Stylianou K; Lioudaki E; Papadimitraki E; Kokologiannakis G; Kroustalakis N; Liotsi C; Giannakakis K; Georgoulias V; Daphnis E
    Nephrol Dial Transplant; 2011 May; 26(5):1742-5. PubMed ID: 21382992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New options for integrating antiangiogenic therapy and platinum-based first-line chemotherapy for advanced non-small-cell lung cancer.
    Manegold C
    Clin Lung Cancer; 2008; 9 Suppl 3():S100-8. PubMed ID: 19419923
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-vascular endothelial growth factor monoclonals in non-small cell lung cancer.
    Sandler AB; Johnson DH; Herbst RS
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4258s-4262s. PubMed ID: 15217970
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance bevacizumab is associated with increased hemoglobin in patients with advanced, nonsquamous, non-small cell lung cancer.
    Riess JW; Logan AC; Krupitskaya Y; Padda S; Clément-Duchêne C; Ganjoo K; Colevas AD; Pedro-Salcedo MS; Kuo CJ; Wakelee HA
    Cancer Invest; 2012 Mar; 30(3):231-5. PubMed ID: 22360362
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab for the treatment of advanced non-small-cell lung cancer.
    Manegold C
    Expert Rev Anticancer Ther; 2008 May; 8(5):689-99. PubMed ID: 18471042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab in non small cell lung cancer.
    Sandler A
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4613-6. PubMed ID: 17671151
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The use of bevacizumab in non-small cell lung cancer: an update.
    Lauro S; Onesti CE; Righini R; Marchetti P
    Anticancer Res; 2014 Apr; 34(4):1537-45. PubMed ID: 24692680
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study.
    Crinò L; Dansin E; Garrido P; Griesinger F; Laskin J; Pavlakis N; Stroiakovski D; Thatcher N; Tsai CM; Wu YL; Zhou C
    Lancet Oncol; 2010 Aug; 11(8):733-40. PubMed ID: 20650686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unanswered questions: monoclonal antibodies in the treatment of advanced non-small-cell lung cancer.
    Gridelli C; Rossi A
    Oncology (Williston Park); 2010 Nov; 24(13):1216-23. PubMed ID: 21192561
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Adverse events related to bevacizumab and the management principles in non-small cell lung cancer].
    Cheng G; Zhang L
    Zhongguo Fei Ai Za Zhi; 2010 Jun; 13(6):563-7. PubMed ID: 20681440
    [No Abstract]   [Full Text] [Related]  

  • 31. Targeting angiogenesis driven by vascular endothelial growth factors using antibody-based therapies.
    Grothey A; Ellis LM
    Cancer J; 2008; 14(3):170-7. PubMed ID: 18536556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perforated viscus in a patient with non-small cell lung cancer receiving bevacizumab.
    Gray J; Murren J; Sharma A; Kelley S; Detterbeck F; Bepler G
    J Thorac Oncol; 2007 Jun; 2(6):571-3. PubMed ID: 17545855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab in advanced lung cancer: in search of the right drug for the right patient.
    Burns TF; Juergens RA
    Oncology (Williston Park); 2010 Nov; 24(13):1223-4, 1226. PubMed ID: 21192562
    [No Abstract]   [Full Text] [Related]  

  • 34. Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events.
    Wu S; Keresztes RS
    Cancer Invest; 2011 Aug; 29(7):460-71. PubMed ID: 21740083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bevacizumab in non-small cell lung cancer: an overview of practice in the era of molecular testing.
    Snee M
    Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):468-72. PubMed ID: 24909702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Osteonecrosis of the humeral head in a patient with non-small cell lung cancer receiving bevacizumab.
    Koczywas M; Cristea MC
    J Thorac Oncol; 2011 Nov; 6(11):1960-1. PubMed ID: 22005475
    [No Abstract]   [Full Text] [Related]  

  • 37. Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer.
    Bertino EM; Otterson GA
    Lung Cancer; 2010 Dec; 70(3):233-46. PubMed ID: 20888062
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab in the treatment of advanced, non-squamous non-small cell lung cancer: an evidence-based approach.
    Tassinari D; Sartori S; Papi M; Drudi F; Castellani C; Carloni F; Tombesi P; Lazzari-Agli L
    Oncology; 2011; 80(5-6):350-8. PubMed ID: 21791945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Antiangiogenic agents: current limits in thoracic oncology].
    Dansin E; Lauridant G; Chahine B
    Bull Cancer; 2012 Nov; 99(11):1083-91. PubMed ID: 23113985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.